<p>Secondary metabolites are vital to human health and strategies to improve their production and detection are equally essential. The blue pigmented metabolite actinorhodin produced by <em>Streptomyces coelicolor</em>, a genus renowned for their diverse secondary metabolites, provides a unique opportunity to identify small molecules probes of secondary metabolism. Small molecules capable of altering secondary metabolism will have widespread application in the streptomycetes due to their ease of addition to any culture condition. Taking advantage of the phenotypic versatility of the <em>S. coelicolor</em> lifecycle, we extended our search for small molecule modulators further to include the entire developmental process. In addition to alterations in secondary metabolism, these processes include growth inhibition, precocious sporulation and alterations in aerial hyphae formation and sporulation. This work provides the foundation for studying <em>Streptomyces</em> by chemical manipulation. Those compounds which stimulate secondary metabolism were narrowed down to 19 ARCs (for antibiotic remodeling compounds). From these, a set of 4 structurally related molecules, the ARC2 series, was identified as weak inhibitors of fatty acid biosynthesis and most likely lead to alterations in secondary metabolism through shifting precursors from primary to secondary metabolism. Consistent with the conservation of fatty acid biosynthesis within bacteria, the effect of the ARC2 series extends in general to the actinomycetes. This provides a simple strategy to alter the secondary metabolic profiles of a diverse range of actinomycetes.</p> / Doctor of Philosophy (PhD)

Yes / The formylpeptide receptor-1 (FPR1) is a member of the chemotactic GPCR-7TM formyl peptide receptor family, whose principle function is in trafficking of various leukocytes into sites of bacterial infection and inflammation. More recently, FPR1 has been shown to be expressed in different types of cancer and in this context, plays a significant role in their expansion, resistance and recurrence. ICT12035 is a selective and potent (30 nM in calcium mobilisation assay) small molecule FPR1 antagonist. Here, we demonstrate the efficacy of ICT12035, in a number of 2D and 3D proliferation and invasion in vitro assays and an in vivo model. Our results demonstrate that targeting FPR1 by a selective small molecule antagonist, such as ICT12035, can provide a new avenue for the treatment of cancers.

Au sein du laboratoire, par une stratégie de conception de médicaments par la méthode des fragments, nous avons généré une nouvelle famille d'inhibiteurs de cyclophilines, les SMCypI (« Small-Molecule Cyclophilin Inhibitors »), non liée aux autres inhibiteurs de cyclophilines existants. Les cyclophilines sont des protéines cellulaires impliquées dans un grand nombre de processus biologiques. Toutefois, les inhibiteurs de cyclophilines disponibles possèdent de nombreux inconvénients qui rendent leur utilisation clinique difficile. Au cours de ma thèse nous nous sommes intéressés au développement des SMCypI dans deux domaines en particulier, la Virologie et l’Hépatologie.Dans le domaine de la Virologie, les cyclophilines sont impliquées dans la réplication de plusieurs virus et constituent donc une cible de choix dans le développement d'antiviraux à large spectre. Dans un premier temps, nous nous sommes intéressés à la caractérisation de l’activité antivirale de ces molécules sur le virus de l’Hépatite C, avec comme objectif de démontrer leur activité pangénotypique, leur haute barrière à la résistance, leur mécanisme d’action et leur activité antivirale à large spectre pour d’autres virus de la famille des Flaviviridae.Dans le domaine de l’Hépatologie, les lésions d’ischémie-reperfusion hépatique sont rencontrés pendant la chirurgie hépatique et la transplantation hépatique. La mitochondrie est un acteur majeur via l’ouverture du pore de transition de perméabilité mitochondrial. L’ouverture du pore est modulée par la cyclophiline D. Dans un deuxième temps, nous avons étudié les effets des SMCypI sur cette deuxième cible. Cela nous a permis de démontrer leur effet hépatoprotecteur dans un modèle murin d’ischémie-reperfusion hépatique.L’ensemble de ces résultats ouvre la porte pour le concept des antiviraux à large spectre, et l’utilité dans le domaine de l’hépatologie comme molécules hépatoprotectrices.... / In our laboratory we previously reported a rational design of a new family of smallmolecule cyclophilins inhibitors, SMCypI, unrelated to other cyclophilins inhibitors by means of a complex fragment-based drug discovery approach. Cyclophilins are cellular proteins involved in multiple biological processes. Unfortunately, different disadvantages have limited their clinical development. The aim my thesis was to study the SMCypI in two particulars fields, Virology and Hepatology.In the field of Virology, cyclophilins inhibitors are involved in viral replication of multiple viruses, which make them a convenient target for the development of “broad-spectrum antivirals”. Here, we first characterized the pangenotypic anti-HCV activity of this new family of SMCypI, with high resistance barrier. We studied its mechanism of action andits broad antiviral activity on other members of the Flaviviridae family.In the field of Hepatology, ischemia-reperfusion injuries occur during liver surgery and liver transplantation. Mitochondria play a central role in the opening of mitochondrial permeability transition pore. The opening of this pore is mainly regulated by cyclophilin D. The aim of the second part of our work was to demonstrated a hepatoprotective effect of the SMCypl in a murine model of hepatic ischemia reperfusion injury.Overall, these results are leading the way to the development of broad-spectrumantiviral drugs and their use in hepatology as hepatoprotective drugs....

The work presented in this Thesis describes the design, synthesis and reactivity of a symmetric and various asymmetric Schiff-base macrocycles that are capable of forming a wedge-shaped “Pacman” conformation upon metal binding. Chapter One introduces catalysts for small molecule transformation as well as transition metal complexes of pyrrole-containing macrocycles. Further to this, Pacman systems, including previous work from Love and co-workers, and complexes capable of secondary coordination-sphere control will be discussed. Chapter Two details the design and synthesis of two asymmetric macrocycles that both contain one neutral and one N₄-donor imine-pyrrole binding pocket, H₂LP and H₂LNMe. The synthesis and characterisation of the series of complexes [M(LP)] and [M(LNMe)] (M = Pd, K₂, Co, VCl, TiCl, Mg, Fe and Mn) and their characteristics highlighted, including the formation of a supramolecular cyclic hexamer. Chapter Three presents the modification of the above ligands at the meso-group, the N-substituent and the non-pyrrolic binding pocket to give H2LFP and H₂LFNMe, H₂LNMes and H₂L(NH)NMe respectively. Palladium and cobalt complexes of these macrocycles were prepared and characterised. Chapter Four describes the design and synthesis of the ligand H₄LEt as well as the synthesis and characterisation of tin-alkyl and mononuclear calcium complexes of LEt, as well as the heterobimetallic complexes [SnMe₂(M)(THF)(LEt)] (M = Zn or Fe). The homobimetallic complexes [M₂(LEt)] (M = Co, Mg and NbCl) are also presented along with a magnesium-cubane structure of LEt in which the cubane is encapsulated by two, bowl-shaped macrocycles. Chapter Five provides a summary of the work presented in this thesis. Chapter Six describes the full experimental details and analytical data for all compounds synthesised in this work.

<p>Electroporation is a biological cell's natural reaction to strong electric fields, where transient pores are created in the cell membrane. While electroporation holds promise of being a safe and effective tool for enhancing molecular delivery in numerous medical applications, it remains largely confined to preclinical research and clinical trials due to an incomplete understanding of the exact mechanisms involved. Muscle fibers are an important delivery target, but traditional theoretical studies of electroporation ignore the individual fiber geometry, making it impossible to study the unique transverse and longitudinal effects from the pulse stimulus. In these long, thin muscle fibers, the total reaction of the fiber to the electric field is due to fundamentally different effects from the constituent longitudinal and transverse components of the electric field generated by the pulse stimulus. While effects from the transverse component have been studied to some degree, the effects from the longitudinal component have not been considered. </p><p>This study develops a model of electroporation and delivery of small molecules in muscle tissue that includes effects from both the transverse and longitudinal components of the electric field. First, an asymptotic model of electric potential in an individual muscle fiber is derived that separates the full 3D boundary value problem into transverse and a longitudinal problems. The transverse and longitudinal problems each have their own respective source functions: the new "transverse activating function" and the well known longitudinal activating function (AF). This separation enhances analysis of the different effects from these two AFs and drastically reduces computational intensity. Electroporation is added to the asymptotic fiber model, and simplified two-compartment mass transport equations are derived from the full 3D conservation of mass equations to allow simulation of molecular uptake due to diffusion and the electric field. Special emphasis is placed on choosing model geometry, electrical, and pulsing parameters that are in accordance with experiments that study electroporation-mediated delivery of small molecules in the skeletal muscle of small mammals.</p><p>Simulations reveal that for fibers close to the electrodes the transverse AF dominates, but for fibers far from the electrodes the longitudinal AF enhances uptake by as much as 2000%. However, on the macroscopic tissue level, the increase in uptake from the longitudinal AF is no more than 10%, given that fibers far from the electrodes contribute so little to the total uptake in the tissue. The mechanism underlying the smaller effect from the longitudinal AF is found to be unique to the process of electroporation itself. Electroporation occurs on the short time scale of polarization via the transverse AF, drastically increases membrane conductance, and effectively precludes further creation of pores from charging of the membrane via the longitudinal AF. The exact value of enhancement in uptake from the longitudinal AF is shown to depend on pulsing, membrane, and tissue parameters. Finally, simulation results reproduce qualitative, and in some cases quantitative, behavior of uptake observed in experiments.</p><p>Overall, percent increase in total tissue uptake from the longitudinal AF is on the order of experimental variability, and this study corroborates previous theoretical models that neglect the effects from the longitudinal AF. However, previous models neglect the longitudinal AF without explanation, while the asymptotic fiber model is able to detail the mechanisms involved. Mechanisms revealed by the model offer insight into interpreting experimental results and increasing efficiency of delivery protocols. The model also rigorously derives a new transverse AF based on individual fiber geometry, which affects the spatial distribution of uptake in tissue differently than predicting uptake based on the magnitude of the electric field, as used in many published models. Results of this study are strictly valid for transport of small molecules through small non-growing pores. For gene therapy applications the model must be extended to transport of large DNA molecules through large pores, which may alter the importance of the longitudinal AF. In broader terms, the asymptotic model also provides a new, computationally efficient tool that may be used in studying the effect of transverse and longitudinal components of the field for other types of membrane dynamics in muscle and nerves.</p> / Dissertation

A crucial step in the biosynthesis of membrane proteins is their incorporation into the hydrophobic environment of the lipid bilayer. In eukaryotic cells this event occurs largely in concert with translation on ribosomes bound to the membrane of the endoplasmic reticulum (ER) at a site termed the ER translocon. This dynamic proteinaceous complex forms an aqueous conduit across the ER membrane and is laterally gated to allow transmembrane (TM) segments to partition into the lipid phase. In the case of polytopic membrane proteins, the coordinated release of multiple TM segments by the ER translocon is a poorly defined process and appears to be highly substratespecific. In this study, the ion channel subunit P2X2 was used as a novel model to examine themolecular details of membrane protein integration at the ER translocon. A primarily in vitro approach was taken using stable biosynthetic intermediates to simulate each stage of the membrane translocation and integration of P2X2. Chemical and photoreactive site-specific cross-linking analyses were then conducted to determine the molecular environment of the P2X2 TM segments throughout biosynthesis. Remarkably, both TM1 and TM2 of P2X2 were found to remain directly adjacent to the ER translocon throughout P2X2 biosynthesis and were only dislocated into the lipid phase by artificial termination of translation and disruption of the ribosome-translocon interaction. Retention of P2X2 TM1 at the ER translocon is maintained despite the synthesis of over 300 amino acid residues separating it from the ribosome peptidyl transferase centre. Premature dislocation of TM1 from the ER translocon site resulted in a pronounced aggregation of TM1 fragments both in vitro and in vivo. This is in stark contrast to previous passive-partitioning models of membrane integration and suggests that the ER translocon regulates the integration of polytopic membrane proteins in order to accommodate the specific requirementsof the substrate protein itself. The detailed characterisation of P2X2 biosynthesis was then exploited in order to examine the effect of a novel small inhibitor of ER translocon function. Eeyarestatin 1 (ESI) was found to cause a substantial inhibition of protein secretion in vivo and dramatically reduced the ER translocation of three distinct classes of substrate, including P2X2, in vitro. Using both a cross-linking analysis and a protease-protection assay for a specialised translocation reaction, ESI was shown to prevent the transfer of the nascent polypeptide chain from the membrane delivery machinery to the ER translocon complex. Further evidence that ESI targets the Sec61 complex is presented and a model for ESI-mediated inhibition of ER translocation is suggested. Taken together these data establish ESI as a novel small molecule inhibitor that selectively inhibits protein translocation both in vitroand in vivo.

Solid-state dye-sensitized solar cells (ssDSSCs) and recently developed perovskite solar cells (PSCs) have attracted a great attention in the scientific field of photovoltaics due to their low cost, absence of solvent, simple fabrication and promising power conversion efficiency (PCE). In these types of solar cell, the dye molecule or the perovskite can harvest the light on the basis of electron excitation. Afterwards, the electron and hole are collected at the charge transport materials. Photoelectrochemical polymerization (PEP) is employed in this thesis to synthesize conducting polymer hole transport materials (HTMs) for ssDSSCs. We have for the first time developed aqueous PEP in comparison with the conventional organic PEP with acetonitrile as solvent. This water-based PEP could potentially provide a low-cost, environmental-friendly method for efficient deposition of polymer HTM for ssDSSCs. In addition, new and simple precursors have been tested with PEP method. The effects of dye molecules on the PEP were also systematically studied, and we found that (a) the bulky structure of dye is of key importance for blocking the interfacial charge recombination; and (b) the matching of the energy levels between the dye and the precursor plays a key role in determining the kinetics of the PEP process. In PSCs, the HTM layer is crucial for efficient charge collection and its long term stability. We have studied different series of new molecular HTMs in order to understand fundamentally the influence of alkyl chains, molecular energy levels, and molecular geometry of the HTM on the photovoltaic performance. We have identified several important factors of the HTMs for efficient PSCs, including high uniformity of the HTM capping layer, perovskite-HTM energy level matching, good HTM solubility, and high conductivity. These factors affect interfacial hole injection, hole transport, and charge recombination in PSCs. By systematical optimization, a promising PCE of 19.8% has been achieved by employing a new HTM H11. We believe that this work could provide important guidance for the future development of new and efficient HTMs for PSCs.

We recently reported results from a high-throughput screening effort that identified 235 inhibitors of the Escherichia coli GroEL/ES chaperonin system [Bioorg. Med. Chem. Lett. 2014, 24, 786]. As the GroEL/ES chaperonin system is essential for growth under all conditions, we reasoned that targeting GroEL/ES with small molecule inhibitors could be a viable antibacterial strategy. Extending from our initial screen, we report here the antibacterial activities of 22 GroEL/ES inhibitors against a panel of Gram-positive and Gram-negative bacteria, including E. coli, Bacillus subtilis, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae. GroEL/ES inhibitors were more effective at blocking the proliferation of Gram-positive bacteria, in particular S. aureus, where lead compounds exhibited antibiotic effects from the low-lM to mid-nM range. While several compounds inhibited the human HSP60/10 refolding cycle, some were able to selectively target the bacterial GroEL/ES system. Despite inhibiting HSP60/10, many compounds exhibited low to no cytotoxicity against human liver and kidney cell lines. Two lead candidates emerged from the panel, compounds 8 and 18, that exhibit >50-fold selectivity for inhibiting S. aureus growth compared to liver or kidney cell cytotoxicity. Compounds 8 and 18 inhibited drug-sensitive and methicillin-resistant S. aureus strains with potencies comparable to vancomycin, daptomycin, and streptomycin, and are promising candidates to explore for validating the GroEL/ES chaperonin system as a viable antibiotic target.

G-quadruplex secondary structures are four-stranded globular nucleic acid structures that form in specific DNA and RNA G-rich sequences with biological significance, such as those found in human telomeres, oncogene promoter regions, replication initiation sites, and 5’- and 3’-untranslated (UTR) regions, which have been identified as novel drug targets. The non-canonical G-quadruplex secondary structures readily form under physiologically relevant ionic conditions, and exhibit great diversity in their topologies and loop conformations depending on the DNA or RNA sequences at hand. The structural diversity of these unique secondary structures is essential to their specific recognition by different regulatory proteins or small molecule compounds. A significant amount of research has been done in this field that provides compelling evidence for the existence, biological significance, and potential druggability of G-quadruplexes. In this dissertation, I explore G-quadruplex formation in the promoters of BCL2, PDGFR-β and c-Myc oncogenes and their interactions with small molecule compounds or proteins. Firstly, I investigated a newly-identified G-quadruplex (P1G4) forming immediately upstream of the human BCL2 gene, which has been found to be overexpressed in several human tumors. In this research, I have found that P1G4 acts as a transcription repressor, and that its inhibitory effect can be enriched by the G-quadruplex-interactive compound, TMPyP4. Both P1G4 and the previously reported Pu39 G-quadruplexes form independently in adjacent regions within the BCL2 P1 promoter, but P1G4 appears to play a more dominant role in repressing transcriptional activity. NMR and CD studies have shown that the P1G4 G-quadruplex appears to comprise a novel dynamic equilibrium of two parallel structures, one regular, with two 1-nt loops and a 12-nt middle loop, and another broken-stranded, with three 1-nt loops and an 11-nt middle loop; both structures adopt a novel hairpin (stem-loop duplex) conformation in the long central loop. This dynamic equilibrium of two closely-related G-quadruplex structures with a unique hairpin loop conformation may provide a specific target for small molecules to modulate BCL2 gene transcription. I also explored the 3’ end G-quadruplex that forms within the core promoter of PDGFR-β, which has also been observed to be present at abnormal levels in a variety of clinical pathologies, including malignancies. The 3′-end G-quadruplex formed in the PDGFR-β promoter NHE appears to be selectively stabilized by an ellipticine analog, GSA1129, which can shift the dynamic equilibrium in the full-length sequence to favor the 3′-end G-quadruplex, and can repress PDGFR-β activity in cancer cell lines. NMR studies in combination with biophysical experiments have shown that in the wild-type extended 3ʼ-end NHE sequences, two novel intramolecular G-quadruplexes can be formed in a potassium solution, one with a 3’-flanking distant guanine inserted into the 3’-external tetrad (3’-insertion G-quadruplex), and another with a 5’-flanking distant guanine inserted into the 5’-external tetrad (5’-insertion G-quadruplex). Further investigation of the elongated PDGFR-β 3′-end sequence containing both the 5’- and 3’- flanking guanine sequences showed the formation of a combination of the two G-quadruplexes existing in equilibrium. Importantly, it was observed that GSA1129 can bind to and increase the stability of each of the end-insertion G-quadruplexes, raising their Tₘ by 25 degrees. This study highlights the dynamic nature of the 3′-end NHE sequence and the importance of identifying the proper sequence for the formation of biologically relevant G-quadruplex structures. Significantly, the dynamic nature of the 3′-end G-quadruplex suggests that it may be an attractive target for drug regulation. I then analyzed two proteins, Nucleolin and NM23-H2, which interact with the c-Myc G-quadruplex structure that forms in the proximal promoter region of the c-Myc gene; this is one of the most commonly deregulated genes in the human neoplasm. Nucleolin is known to be a transcriptional repressor for c-Myc, binding to and stabilizing the c-Myc G-quadruplex, whereas NM23-H2 is known to be a transcriptional activator that unwinds and destabilizes the c-Myc G-quadruplex. An investigation of the molecular mechanisms of the interaction between the c-Myc G-quadruplex and nucleolin showed that the minimal binding domains required for a tight binding of the protein to the c-Myc G-quadruplex are the four RNA binding domains (RBDs) of nucleolin, referred to as Nuc1234, and that the RGG domain is unnecessary for c-Myc G-quadruplex binding. The stable G-quadruplex formed within Pu27 using G-tract runs I, II, IV and V was determined to be the best substrate (Myc1245T) for nucleolin binding, showing the highest affinity. 3D NMR experiments performed on the free protein Nuc1234 and its complex with the Myc1245T G-quadruplex have shown that upon complex formation, only the disordered linker regions of the protein display significant chemical shift changes, whereas most other residues show chemical shift values similar to those of the free protein. The c-Myc G-quadruplex has three loops that flip outward in a solvent containing K⁺, according to its structure. The hypothesis for this association is that nucleolin wraps around the G-quadruplex and interacts specifically with the flipped-outward loop regions of the c-Myc G-quadruplex via its own inter-RBD linker regions, with little structural change in the RBDs themselves. A definitive determination of the 3D molecular structure of nucleolin and its complex with Myc1245T is currently in development. Biophysical and structural studies were then conducted to investigate the interactions of the protein NM23-H2/NDP kinase B with the c-Myc G-quadruplex. NM23-H2 binds to single-stranded guanine- and cytosine-rich sequences, but not to double-stranded DNA in the NHE III₁ region; the binding therefore appears structure-specific, rather than sequence-specific. Moreover, increasing concentrations of the strong G-quadruplex-interactive compound TMPyP4, a porphyrin-based drug, inhibits the binding of NM23-H2 to the NHE III₁ region; this suggests that the stabilization of the G-quadruplex hinders the recognition and remodeling function of the NM23-H2. By conducting Forster Resonance Energy Transfer (FRET) assays in combination with Circular Dichroism (CD) studies, I demonstrated that NM23-H2 can actively resolve the c-Myc G-quadruplex. Taken together, these results show that the use of small molecules to prevent NM23-H2 from binding to and resolving the NHE III₁ region G-quadruplex may have the potential to inhibit c-Myc transcription for cancer therapeutic purposes. This underlines the importance of understanding the mechanism of function operating between NM23-H2 and the c-Myc G-quadruplex. Understanding molecular mechanism between NM23-H2 and c-Myc is under investigation.

Defective DNA repair capacity has been shown to be a common feature of cancer, and loss of function mutations in 'stability' genes that normally maintain the integrity of the genome may prove a key rate-limiting step in carcinogenesis. Since even genetically unstable cells require some repair functionality to maintain viability, these cancers likely exhibit an over-reliance on other DNA repair pathways for survival. Therapeutically targeting backup repair processes in such tumours represents a novel means by which to achieve selective tumour toxicity. Full exploitation of these synthetic lethal interactions will require an in-depth knowledge of the genetic basis of DNA repair in combination with an armoury of small molecule inhibitors of cellular targets. To this end, we have designed, optimised and run two high-throughput cell-based screens to identify genes and small molecules that can modulate mismatch repair (MMR) activity. Key to these screening strategies are the resistance of cells with dysfunctional MMR to a range of cytotoxic drugs, including the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). By exploiting this MMR-dependent toxicity we have assayed for siRNA and small molecules that permit the survival of MNNG-treated MMR-proficient cells to levels comparable to MMR-deficient cells, and which therefore represent putative MMR modulating agents. A screen of 571 siRNA for gene depletions that reduce MNNG sensitivity by at least two population standard deviations identified 10 genes of potential interest, and included the four canonical MMR genes, MSH2 (2.87 ± 0.28 (Z ± SE)), MSH6 (4.87 ± 0.06), MLH1 (3.42 ± 0.43) and PMS2 (3.36 ± 0.44). TDG represented an unexpected hit that decreased MNNG sensitivity by 2.55 ± 0.04 population standard deviations. However, clonogenic survival experiments found TDG depletion to be contextual synthetic lethal within an MMR-null background when treated with MNNG, reducing HCT116 clonogenicity by 37% (p < 0.001). Moreover, TDG knockdown increased the number of 53 binding protein 1 (53bp1) foci in MMR-proficient cells by 40% and MMR–deficient cells by 27% following MNNG exposure (p < 0.001). Combined with a failure to replicate the primary screen result, the role for TDG in the response to MNNG could be explained solely through its established role as a member of the base excision repair pathway. A second screen of the NCI Diversity I and II small molecule libraries (n=1786) was conducted to identify putative MMR inhibitors. Subsequent analysis revealed NSC197049 to increase cellular viability of MNNG treated cells by 3.60±0.32 population standard deviations and was successfully validated as a hit. Co-treatment of NSC197049 with MNNG conferred dose-dependent chemoprotection independently of MMR status and cell line, an effect that was lost if NSC197049 was pre- or post-treated. The protection was associated with a reduction in MNNG-dependent 53bp1 foci of 60% in MMR proficient cells and 15% in MMR deficient cells (p < 0.001), together with a marked reduction of > 80% in subG1 content at 48 hours post-MNNG that was independent of MMR status. Interestingly, the characteristic G2/M arrest of MNNG-treated MMR-proficient cells remained intact (~40% arrested). Taken together, these observations are not consistent with NSC197049 acting as an inhibitor of MMR. Dithiolthiones have been described as chemoprotective agents that induce antioxidant defences, whilst we have found NSC197049 phenocopies known antioxidants ascorbic acid and glutathione in protecting against MNNG-induced toxicity. NSC197049 may therefore act by bolstering cellular antioxidant defences. The precise mechanism may be novel, since the proto-typical dithiolthione, Oltipraz, failed to be protective in this study. In summary, we have confirmed that MMR is the primary determinant of MNNG sensitivity, and found that TDG is unlikely to be involved in MMR. We have also identified a novel chemoprotective small molecule that is unlikely to represent an MMR inhibitor, but that might be useful in cancer chemoprevention.